ATE404536T1 - Substituierte chinolinderivate als inhibitoren von mitotischem kinesin - Google Patents
Substituierte chinolinderivate als inhibitoren von mitotischem kinesinInfo
- Publication number
- ATE404536T1 ATE404536T1 AT05752901T AT05752901T ATE404536T1 AT E404536 T1 ATE404536 T1 AT E404536T1 AT 05752901 T AT05752901 T AT 05752901T AT 05752901 T AT05752901 T AT 05752901T AT E404536 T1 ATE404536 T1 AT E404536T1
- Authority
- AT
- Austria
- Prior art keywords
- inhibitors
- substituted quinoline
- quinoline derivatives
- mitotic kinesin
- compounds
- Prior art date
Links
- 102000010638 Kinesin Human genes 0.000 title 1
- 108010063296 Kinesin Proteins 0.000 title 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000000394 mitotic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000003937 drug carrier Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57312004P | 2004-05-21 | 2004-05-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE404536T1 true ATE404536T1 (de) | 2008-08-15 |
Family
ID=34970815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05752901T ATE404536T1 (de) | 2004-05-21 | 2005-05-19 | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7452996B2 (de) |
| EP (1) | EP1753723B1 (de) |
| JP (1) | JP2008502721A (de) |
| CN (1) | CN1956960A (de) |
| AT (1) | ATE404536T1 (de) |
| AU (1) | AU2005245492A1 (de) |
| BR (1) | BRPI0511433A (de) |
| CA (1) | CA2564215A1 (de) |
| DE (1) | DE602005008953D1 (de) |
| DK (1) | DK1753723T3 (de) |
| ES (1) | ES2311992T3 (de) |
| HR (1) | HRP20080493T3 (de) |
| MX (1) | MXPA06011958A (de) |
| PL (1) | PL1753723T3 (de) |
| PT (1) | PT1753723E (de) |
| RS (1) | RS50670B (de) |
| RU (1) | RU2385867C2 (de) |
| SI (1) | SI1753723T1 (de) |
| WO (1) | WO2005113507A1 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2564215A1 (en) * | 2004-05-21 | 2005-12-01 | Chiron Corporation | Substituted quinoline derivatives as mitotic kinesin inhibitors |
| BRPI0514390A (pt) | 2004-08-18 | 2008-06-10 | Astrazeneca Ab | enanciÈmero de um composto ou um sal farmacêuticamente aceitável ou um éster hidrolisável in vivo do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para produzir um efeito inibidor de eg5 em um animal de sangue quente e para tratar doenças, e, composição farmacêutica |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| JP2009514900A (ja) * | 2005-11-04 | 2009-04-09 | スミスクライン・ビーチャム・コーポレイション | 血糖降下剤の投与方法 |
| GEP20135728B (en) | 2006-10-09 | 2013-01-25 | Takeda Pharmaceuticals Co | Kinase inhibitors |
| MX2009005071A (es) * | 2006-11-13 | 2009-05-25 | Novartis Ag | Compuestos de pirazol y triazol sustituidos como inhibidores de ksp. |
| CA2674318A1 (en) * | 2007-01-05 | 2008-07-17 | Novartis Ag | Cyclized derivatives as eg-5 inhibitors |
| FR2940289B1 (fr) * | 2008-12-23 | 2014-09-12 | Biopharmed | Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas |
| TH121482A (th) | 2009-08-19 | 2013-02-28 | นางสาวปัณณพัฒน์ เหลืองธาตุทอง | องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน |
| WO2011128388A2 (en) * | 2010-04-15 | 2011-10-20 | Novartis Ag | Oxazole and thiazole compounds as ksp inhibitors |
| EA201201404A1 (ru) * | 2010-04-15 | 2013-04-30 | Новартис Аг | Триазолы как ингибиторы кбв (кинезин-белок веретена) |
| EP3444363B1 (de) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarker zur vorhersage und beurteilung des ansprechens von schilddrüsen- und nierenkrebspatienten auf lenvatinibverbindungen |
| RU2486175C2 (ru) * | 2011-09-12 | 2013-06-27 | Закрытое Акционерное Общество "Фарм-Синтез" | Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений |
| US9458161B1 (en) | 2011-11-03 | 2016-10-04 | Vanderblit University | TSPO ligands for cancer imaging and treatment |
| EP2882436A1 (de) * | 2012-08-13 | 2015-06-17 | Array Biopharma, Inc. | Arry-520 zur verwendung bei der behandlung von krebs bei patienten mit niedrigem aag |
| KR20230043234A (ko) | 2014-08-28 | 2023-03-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| KR20180037953A (ko) * | 2015-08-19 | 2018-04-13 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 담관암을 위한 치료제 |
| CA2994925C (en) | 2015-08-20 | 2023-08-29 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| BR112019023064A2 (pt) | 2017-05-16 | 2020-06-09 | Eisai R&D Man Co Ltd | tratamento de carcinoma hepatocelular |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6172087B1 (en) * | 1998-06-03 | 2001-01-09 | Gpi Nil Holding, Inc. | N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses |
| EP1165519A1 (de) | 1999-04-02 | 2002-01-02 | Neurogen Corporation | Aryl und heteroaryl kondensierte aminoalkylimidazolderivate und ihre verwendung als antidiabetika |
| US6545004B1 (en) * | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| BR0015110A (pt) | 1999-10-27 | 2002-07-02 | Cytokinetics Inc | Métodos de tratamento de doenças de proliferação celular, de tratamento de um distúrbio associado com a atividade da cinesina ksp, de inibição da cinesina ksp, de triagem de moduladores da cinesina kps e de triagem de compostos que se ligam na cinesina ksp, e, compostos |
| MXPA03003039A (es) | 2000-10-06 | 2003-10-15 | Neurogen Corp | Derivados de indola y bencimidazola como moduladores del receptor crf. |
| US6964967B2 (en) | 2000-12-11 | 2005-11-15 | Amgen, Inc. | Substituted pyrido[2,3-d]pyrimidines and methods for their use |
| WO2002057244A1 (en) | 2001-01-19 | 2002-07-25 | Cytokinetics, Inc. | Phenothiazine kinesin inhibitors |
| US20040132830A1 (en) | 2001-01-19 | 2004-07-08 | Finer Jeffrey T | Triphenylmethane kinesin inhibitors |
| EP1444209A4 (de) | 2001-11-07 | 2005-02-16 | Merck & Co Inc | Inhibitoren mitotischer kinesine |
| US6753428B2 (en) | 2001-11-20 | 2004-06-22 | Cytokinetics, Inc. | Process for the racemization of chiral quinazolinones |
| JP4467979B2 (ja) | 2001-12-06 | 2010-05-26 | メルク・シャープ・エンド・ドーム・コーポレイション | 有糸分裂キネシン阻害剤 |
| ATE372341T1 (de) | 2001-12-06 | 2007-09-15 | Merck & Co Inc | Inhibitoren von mitotischem kinesin |
| WO2003049527A2 (en) | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| JP2005515208A (ja) | 2001-12-06 | 2005-05-26 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂性キネシン阻害剤 |
| JP4391825B2 (ja) | 2001-12-06 | 2009-12-24 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂キネシン阻害剤 |
| WO2003059289A2 (en) | 2002-01-10 | 2003-07-24 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues |
| WO2003070701A2 (en) | 2002-02-15 | 2003-08-28 | Cytokinetics, Inc. | Syntheses of quinazolinones |
| WO2003079973A2 (en) | 2002-03-08 | 2003-10-02 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| ATE471931T1 (de) * | 2002-04-17 | 2010-07-15 | Cytokinetics Inc | Verbindungen, zusammensetzungen und verfahren |
| WO2003094839A2 (en) | 2002-05-09 | 2003-11-20 | Cytokinetics, Inc. | Pyrimidinone compounds, compositions and methods |
| AU2003270015A1 (en) | 2002-05-09 | 2003-12-02 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| US20050234080A1 (en) | 2002-05-23 | 2005-10-20 | Coleman Paul J | Mitotic kinesin inhibitors |
| JP2005536475A (ja) | 2002-05-23 | 2005-12-02 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、および方法 |
| KR20050010515A (ko) | 2002-06-14 | 2005-01-27 | 머크 앤드 캄파니 인코포레이티드 | 유사분열 키네신 억제제 |
| US7301028B2 (en) | 2002-06-14 | 2007-11-27 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| EP1556357A4 (de) * | 2002-06-14 | 2006-09-13 | Cytokinetics Inc | Verbindungen, zusammensetzungen und verfahren |
| WO2004004652A2 (en) | 2002-07-08 | 2004-01-15 | Merck & Co., Inc. | Mitotic kinesin binding site |
| WO2004006865A2 (en) | 2002-07-17 | 2004-01-22 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| EP1537089A4 (de) | 2002-07-23 | 2008-04-16 | Cytokinetics Inc | Verbindungen, zusammenstellungen und verfahren |
| AU2003262747A1 (en) | 2002-08-21 | 2004-03-11 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| JP2005539062A (ja) | 2002-09-13 | 2005-12-22 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
| CA2564215A1 (en) * | 2004-05-21 | 2005-12-01 | Chiron Corporation | Substituted quinoline derivatives as mitotic kinesin inhibitors |
-
2005
- 2005-05-19 CA CA002564215A patent/CA2564215A1/en not_active Abandoned
- 2005-05-19 PL PL05752901T patent/PL1753723T3/pl unknown
- 2005-05-19 DK DK05752901T patent/DK1753723T3/da active
- 2005-05-19 ES ES05752901T patent/ES2311992T3/es not_active Expired - Lifetime
- 2005-05-19 SI SI200530384T patent/SI1753723T1/sl unknown
- 2005-05-19 PT PT05752901T patent/PT1753723E/pt unknown
- 2005-05-19 US US11/133,509 patent/US7452996B2/en not_active Expired - Fee Related
- 2005-05-19 JP JP2007527522A patent/JP2008502721A/ja active Pending
- 2005-05-19 DE DE602005008953T patent/DE602005008953D1/de not_active Expired - Lifetime
- 2005-05-19 WO PCT/US2005/017961 patent/WO2005113507A1/en not_active Ceased
- 2005-05-19 EP EP05752901A patent/EP1753723B1/de not_active Expired - Lifetime
- 2005-05-19 RU RU2006145336/04A patent/RU2385867C2/ru not_active IP Right Cessation
- 2005-05-19 HR HR20080493T patent/HRP20080493T3/xx unknown
- 2005-05-19 RS RSP-2008/0534A patent/RS50670B/sr unknown
- 2005-05-19 AU AU2005245492A patent/AU2005245492A1/en not_active Abandoned
- 2005-05-19 AT AT05752901T patent/ATE404536T1/de not_active IP Right Cessation
- 2005-05-19 BR BRPI0511433-0A patent/BRPI0511433A/pt not_active IP Right Cessation
- 2005-05-19 CN CNA2005800164405A patent/CN1956960A/zh active Pending
- 2005-05-19 MX MXPA06011958A patent/MXPA06011958A/es active IP Right Grant
-
2008
- 2008-09-30 US US12/242,360 patent/US20090028858A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SI1753723T1 (sl) | 2009-04-30 |
| PL1753723T3 (pl) | 2009-01-30 |
| RS50670B (sr) | 2010-06-30 |
| RU2006145336A (ru) | 2008-06-27 |
| CN1956960A (zh) | 2007-05-02 |
| US20090028858A1 (en) | 2009-01-29 |
| US20050261337A1 (en) | 2005-11-24 |
| EP1753723A1 (de) | 2007-02-21 |
| PT1753723E (pt) | 2008-11-19 |
| US7452996B2 (en) | 2008-11-18 |
| BRPI0511433A (pt) | 2007-12-11 |
| DK1753723T3 (da) | 2008-10-20 |
| CA2564215A1 (en) | 2005-12-01 |
| HRP20080493T3 (hr) | 2009-02-28 |
| MXPA06011958A (es) | 2006-12-15 |
| WO2005113507A1 (en) | 2005-12-01 |
| RU2385867C2 (ru) | 2010-04-10 |
| DE602005008953D1 (de) | 2008-09-25 |
| AU2005245492A1 (en) | 2005-12-01 |
| EP1753723B1 (de) | 2008-08-13 |
| JP2008502721A (ja) | 2008-01-31 |
| ES2311992T3 (es) | 2009-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE404536T1 (de) | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin | |
| MX2007004699A (es) | Derivados de indol y bencimidazol. | |
| TW200612958A (en) | Substituted imidazole derivatives | |
| MX2009007260A (es) | Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5). | |
| TW200626610A (en) | Analogs of 17-hydroxywortmannin as PI3K inhibitors | |
| DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
| ATE495176T1 (de) | Spiroindolinon-derivate | |
| MX2013004733A (es) | Inhibidores de n1/n2-lactama acetil-coa carboxilasa. | |
| PH12012500903A1 (en) | N1 - pyrazolospiroketone acetyl-coa carboxylase inhibitors | |
| ATE253545T1 (de) | Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren | |
| ATE517882T1 (de) | Chinolinderivate | |
| SMT201300109B (it) | Imidazopiridazincarbonitrili utili come inibitori di chinasi | |
| MX2012009186A (es) | Pirrolidina-2-carboxamidas sustituidas. | |
| EA201200049A1 (ru) | 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17 | |
| PT1940839E (pt) | Inibidores de piridopirimidinona pi3k alfa | |
| EA201170176A1 (ru) | Ингибитор stat3, содержащий хинолинкарбоксамидное производное в качестве активного ингредиента | |
| MX2012003982A (es) | Pirrolidinas n-substituidas. | |
| EA200900631A1 (ru) | Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена) | |
| FI20115234A0 (fi) | Uusia pyridatsinoni- ja pyridoniyhdisteitä | |
| MY147188A (en) | Substituted imidazole compounds as ksp inhibitors | |
| DE602007011434D1 (de) | 1h-indol-5-ylpiperazin-1-ylmethanonderivate | |
| EA200901504A1 (ru) | Производные пиразолона, как ингибиторы pde4 | |
| ATE449776T1 (de) | Pyrroloä2,3-cüpyridinderivate | |
| ATE466007T1 (de) | 5-substituierte indol-2-carbonsäureamidderivate | |
| EA200801549A1 (ru) | Новые производные фенантридина в качестве антагонистов брадикинина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1753723 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |